• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

XPO1 基因的反复突变及其对原发性纵隔 B 细胞淋巴瘤中核输出化合物选择性抑制剂敏感性的影响。

Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma.

机构信息

Departement of Hematology, Inserm U918, Centre Henri Becquerel, Rouen, France.

Departement of Hematology, Inserm U955 Team 09, APHP Hospital Henri Mondor, Créteil, France.

出版信息

Am J Hematol. 2016 Sep;91(9):923-30. doi: 10.1002/ajh.24451. Epub 2016 Jul 4.

DOI:10.1002/ajh.24451
PMID:27312795
Abstract

Primary mediastinal B-cell lymphoma (PMBL) is an entity of B-cell lymphoma distinct from the other molecular subtypes of diffuse large B-cell lymphoma (DLBCL). We investigated the prevalence, specificity, and clinical relevance of mutations of XPO1, which encodes a member of the karyopherin-β nuclear transporters, in a large cohort of PMBL. PMBL cases defined histologically or by gene expression profiling (GEP) were sequenced and the XPO1 mutational status was correlated to genetic and clinical characteristics. The XPO1 mutational status was also assessed in DLBCL, Hodgkin lymphoma (HL) and mediastinal gray-zone lymphoma (MGZL).The biological impact of the mutation on Selective Inhibitor of Nuclear Export (SINE) compounds (KPT-185/330) sensitivity was investigated in vitro. XPO1 mutations were present in 28/117 (24%) PMBL cases and in 5/19 (26%) HL cases but absent/rare in MGZL (0/20) or DLBCL (3/197). A higher prevalence (50%) of the recurrent codon 571 variant (p.E571K) was observed in GEP-defined PMBL and was associated with shorter PFS. Age, International Prognostic Index and bulky mass were similar in XPO1 mutant and wild-type cases. KPT-185 induced a dose-dependent decrease in cell proliferation and increased cell-death in PMBL cell lines harboring wild type or XPO1 E571K mutant alleles. Experiments in transfected U2OS cells further confirmed that the XPO1 E571K mutation does not have a drastic impact on KPT-330 binding. To conclude the XPO1 E571K mutation represents a genetic hallmark of the PMBL subtype and serves as a new relevant PMBL biomarker. SINE compounds appear active for both mutated and wild-type protein. Am. J. Hematol. 91:923-930, 2016. © 2016 Wiley Periodicals, Inc.

摘要

原发性纵隔 B 细胞淋巴瘤(PMBL)是一种独特的 B 细胞淋巴瘤实体,与其他弥漫性大 B 细胞淋巴瘤(DLBCL)的分子亚型不同。我们研究了核输出载体家族成员 XPO1 基因突变在 PMBL 大样本中的流行率、特异性和临床相关性。通过组织学或基因表达谱(GEP)定义的 PMBL 病例进行测序,并将 XPO1 突变状态与遗传和临床特征相关联。还评估了 XPO1 突变在 DLBCL、霍奇金淋巴瘤(HL)和纵隔灰色区淋巴瘤(MGZL)中的状态。在体外研究了突变对选择性核输出抑制剂(SINE)化合物(KPT-185/330)敏感性的生物学影响。XPO1 突变存在于 117 例 PMBL 病例中的 28 例(24%)和 19 例 HL 病例中的 5 例(26%)中,但在 20 例 MGZL 或 197 例 DLBCL 中不存在/罕见。在 GEP 定义的 PMBL 中观察到更常见的重复密码子 571 变体(p.E571K),与较短的 PFS 相关。XPO1 突变和野生型病例的年龄、国际预后指数和肿块大小相似。KPT-185 以剂量依赖性方式降低携带野生型或 XPO1 E571K 突变等位基因的 PMBL 细胞系的细胞增殖并增加细胞死亡。在转染的 U2OS 细胞中的实验进一步证实,XPO1 E571K 突变对 KPT-330 结合没有明显影响。总之,XPO1 E571K 突变代表 PMBL 亚型的遗传特征,并作为新的相关 PMBL 生物标志物。SINE 化合物对突变型和野生型蛋白均有效。Am. J. Hematol. 91:923-930, 2016. © 2016 Wiley Periodicals, Inc.

相似文献

1
Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma.XPO1 基因的反复突变及其对原发性纵隔 B 细胞淋巴瘤中核输出化合物选择性抑制剂敏感性的影响。
Am J Hematol. 2016 Sep;91(9):923-30. doi: 10.1002/ajh.24451. Epub 2016 Jul 4.
2
A first-in-class inhibitor of HSP110 to potentiate XPO1-targeted therapy in primary mediastinal B-cell lymphoma and classical Hodgkin lymphoma.一种新型 HSP110 抑制剂,增强了 XPO1 靶向治疗在原发性纵隔 B 细胞淋巴瘤和经典霍奇金淋巴瘤中的作用。
J Exp Clin Cancer Res. 2024 May 22;43(1):148. doi: 10.1186/s13046-024-03068-x.
3
STAT6 is a cargo of exportin 1: Biological relevance in primary mediastinal B-cell lymphoma.STAT6 是输出蛋白 1 的货物:原发性纵隔 B 细胞淋巴瘤中的生物学相关性。
Cell Signal. 2018 Jun;46:76-82. doi: 10.1016/j.cellsig.2018.02.016. Epub 2018 Mar 1.
4
Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma.经典型霍奇金淋巴瘤患者肿瘤及游离循环DNA中输出蛋白1复发性突变的检测及预后价值
Haematologica. 2016 Sep;101(9):1094-101. doi: 10.3324/haematol.2016.145102. Epub 2016 Jun 13.
5
Exportin 1-mediated nuclear/cytoplasmic trafficking controls drug sensitivity of classical Hodgkin's lymphoma.Exportin 1 介导的核质转运控制经典霍奇金淋巴瘤的药物敏感性。
Mol Oncol. 2023 Dec;17(12):2546-2564. doi: 10.1002/1878-0261.13386. Epub 2023 Apr 21.
6
EBV-Positive Primary Large B-Cell Lymphoma: The Role of Immunohistochemistry and XPO1 in the Diagnosis of Mediastinal Lymphomas.EBV 阳性原发性大 B 细胞淋巴瘤:免疫组织化学和 XPO1 在纵隔淋巴瘤诊断中的作用。
Appl Immunohistochem Mol Morphol. 2020 Nov/Dec;28(10):725-730. doi: 10.1097/PAI.0000000000000820.
7
Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185.核输出选择性抑制剂(SINE)XPO1拮抗剂KPT-185对核糖体生物合成和翻译通量的抑制作用
PLoS One. 2015 Sep 4;10(9):e0137210. doi: 10.1371/journal.pone.0137210. eCollection 2015.
8
Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.核输出选择性抑制剂(SINE)化合物的抗肿瘤活性,在非霍奇金淋巴瘤中通过与mTOR抑制剂及地塞米松联合使用而增强。
Cancer Lett. 2016 Dec 28;383(2):309-317. doi: 10.1016/j.canlet.2016.09.016. Epub 2016 Sep 28.
9
Mutation Modifies Exportin 1 Localisation and Interactome in B-cell Lymphoma.突变改变B细胞淋巴瘤中输出蛋白1的定位和相互作用组。
Cancers (Basel). 2020 Sep 30;12(10):2829. doi: 10.3390/cancers12102829.
10
XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy.B细胞血液系统恶性肿瘤中的XPO1:从复发性体细胞突变到靶向治疗
J Hematol Oncol. 2017 Feb 14;10(1):47. doi: 10.1186/s13045-017-0412-4.

引用本文的文献

1
Detection of Gene Mutation from Cell-Free DNA in Blood Circulation of Lymphoma Patients by FAST-COLD PCR.通过快速冷循环聚合酶链反应检测淋巴瘤患者血液循环中游离DNA的基因突变
Int J Mol Sci. 2025 Jul 29;26(15):7324. doi: 10.3390/ijms26157324.
2
Liquid Biopsy in B and T Cell Lymphomas: From Bench to Bedside.B细胞和T细胞淋巴瘤的液体活检:从实验台到病床旁
Int J Mol Sci. 2025 May 19;26(10):4869. doi: 10.3390/ijms26104869.
3
Circulating tumor DNA in lymphoma: technologies and applications.淋巴瘤中的循环肿瘤DNA:技术与应用
J Hematol Oncol. 2025 Mar 11;18(1):29. doi: 10.1186/s13045-025-01673-7.
4
XPO1/Exportin-1 in Acute Myelogenous Leukemia; Biology and Therapeutic Targeting.急性髓系白血病中的XPO1/输出蛋白1;生物学特性与治疗靶点
Biomolecules. 2025 Jan 24;15(2):175. doi: 10.3390/biom15020175.
5
Prognostic and functional role of the nuclear export receptor 1 (XPO1) in gastrointestinal cancers: a potential novel target?核输出受体1(XPO1)在胃肠道癌症中的预后和功能作用:一个潜在的新靶点?
Mol Biol Rep. 2024 Dec 27;52(1):87. doi: 10.1007/s11033-024-10169-5.
6
Selinexor combined with bortezomib, lenalidomide, and dexamethasone for the treatment of newly diagnosed multiple myeloma with extramedullary disease.塞利尼索联合硼替佐米、来那度胺和地塞米松治疗伴有髓外疾病的新诊断多发性骨髓瘤。
Sci Rep. 2024 Nov 19;14(1):28557. doi: 10.1038/s41598-024-79537-2.
7
B Cell Differentiation and the Origin and Pathogenesis of Human B Cell Lymphomas.B 细胞分化与人类 B 细胞淋巴瘤的起源和发病机制。
Methods Mol Biol. 2025;2865:1-30. doi: 10.1007/978-1-0716-4188-0_1.
8
Unraveling the complexity of drug resistance mechanisms to SINE, T cell-engaging therapies and CELMoDs in multiple myeloma: a comprehensive review.解析多发性骨髓瘤中对SINE、T细胞衔接疗法和CELMoDs耐药机制的复杂性:一项全面综述
Cancer Drug Resist. 2024 Jun 26;7:26. doi: 10.20517/cdr.2024.39. eCollection 2024.
9
Multimodal integration of clinic, pathology, and genomics for a rare diagnosis of EBV-positive primary mediastinal large B-cell lymphoma.临床、病理和基因组学的多模态整合用于罕见的EB病毒阳性原发性纵隔大B细胞淋巴瘤诊断
Virchows Arch. 2024 Nov;485(5):931-936. doi: 10.1007/s00428-024-03836-2. Epub 2024 Jun 4.
10
The nuclear export protein exportin-1 in solid malignant tumours: From biology to clinical trials.实体恶性肿瘤中的核输出蛋白 exportin-1:从生物学到临床试验。
Clin Transl Med. 2024 May;14(5):e1684. doi: 10.1002/ctm2.1684.